Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon-Reference-Cited by-同舟云学术

Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon

Published:2024-01-06 Issue:1 Volume:23 Page:204-219
ISSN:2195-9595
Container-title:Current Hepatology Reports
language:en
Short-container-title:Curr Hepatology Rep

Author:

Arnold Jorge^ORCID,Idalsoaga Francisco^ORCID,Díaz Luis Antonio^ORCID,Cabrera Daniel^ORCID,Barrera Francisco^ORCID,Arab Juan Pablo^ORCID,Arrese Marco^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11901-023-00629-0.pdf

Reference124 articles.

1. •• Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023;101133. https://doi.org/10.1016/j.aohep.2023.101133. A landmark paper describing the process leading to a new nomenclature of fatty liver diseases.

2. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851–61. https://doi.org/10.1016/S2468-1253(22)00165-0.

3. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:2809-17.e28. https://doi.org/10.1016/j.cgh.2021.12.002.

4. Wong VW-S, Ekstedt M, Wong GL-H, Hagström H. Changing epidemiology, global trends, and implications for outcomes of NAFLD. J Hepatol. 2023;79:842–52. https://doi.org/10.1016/j.jhep.2023.04.036.

5. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47. https://doi.org/10.1097/HEP.0000000000000004.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease;Annals of Hepatology;2024-07

2. Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH);Annals of Pharmacotherapy;2024-06-17